{
    "organizations": [],
    "uuid": "c2e53e842750cbde29a6c3bc156b871d1829d70c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-innopharmax-signs-license-agreemen/brief-innopharmax-signs-license-agreement-with-shandong-based-pharmaceutical-firm-idUSL3N1R91PY",
    "ord_in_thread": 0,
    "title": "BRIEF-Innopharmax signs license agreement with Shandong-based pharmaceutical firm",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27(Reuters) - Innopharmax Inc\n* Says it signs license agreement with a Shandong-based pharmaceutical firm\n* Says it grants Sapropterin Dihydrochloride (BH4) related exclusive right to the Shandong-based firm in China and Spain\nSource text in Chinese: goo.gl/is466A\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-03-27T10:42:00.000+03:00",
    "crawled": "2018-03-27T11:42:23.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "innopharmax",
        "inc",
        "say",
        "sign",
        "license",
        "agreement",
        "pharmaceutical",
        "firm",
        "say",
        "grant",
        "sapropterin",
        "dihydrochloride",
        "bh4",
        "related",
        "exclusive",
        "right",
        "firm",
        "china",
        "spain",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}